About Zoll

Born in 1952, ZOLL Medical has been manufacturing and designing defibrillator technology for over 60 years and it all started with the Chief of the Cardiac Clinic at Beth Israel Hospital.

And that man was Paul M. Zoll, M.D.

He demonstrated that external electrical stimulation of a patient’s chest during cardiac arrest could produce an effective heartbeat and four years later in 1956, he became the first physician to successfully use external defibrillation to regulate heart rhythms in patients.

This discovery helped to contribute to the decreasing in the heart disease mortality rates and along with his technical collaborators, Dr. Zoll developed a way to display the hearts cardiac activity on an oscilloscopic screen.

In 1964, Dr. Zoll developed a method for long term direct electrical heart stimulation through an implanted pacemaker which has lead to the development of implanted cardiac pacemakers today.

After a number of years developing pacemakers, defibrillators and monitors, Zoll Medical becomes a public company in 1992 with an initial public offering of 2.1 million shares, which generates $14.6 million.

This preceded the launch of the ZOLL 1600 AED in 1995, the first fully upgradeable and configurable AED/manual external defibrillator which was small, easy to use and designed for use by first responders, emergency services and paramedics.

In more recent times, the Zoll AED Plus was designed in 2001 in cooperation with the Burlington, Mass. Police Department and hundreds of other first responders and emergency service agencies.

In 2010, ZOLL Medical were awarded the British Heart Foundation tender for defibrillators and in the following year, Welsh Ambulances NHS Trust awarded Zoll their largest contract to date for the E series defibrillator in the UK.

This year’s developments at ZOLL have seen the company place their AED Plus defibrillators within the Dubai Police Department and their patrol cars whilst the American organisation the FDA has approved the ZOLL ResQCPR System which is said to ‘profoundly increase blood flow to the heart and other vital organs in pre-clinical studies’.